This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA) and Revolution Medicines (RVMD)

Tipranks - Tipranks - Tue Jun 23, 6:26AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Teva Pharmaceutical (TEVA) and Revolution Medicines (RVMD) with bullish sentiments.

TipRanks' Prime Week Sale - 70% Off

Teva Pharmaceutical (TEVA)

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Teva Pharmaceutical, with a price target of $40.00. The company’s shares closed last Thursday at $31.48.

According to TipRanks.com, Chen is a 4-star analyst with an average return of 3.4% and a 46.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Johnson & Johnson. ;'>

Teva Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $42.38, implying a 30.9% upside from current levels. In a report issued on June 15, J.P. Morgan also maintained a Buy rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Revolution Medicines (RVMD)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Revolution Medicines today and set a price target of $182.00. The company’s shares closed last Thursday at $162.99.

According to TipRanks.com, Timashev is a 5-star analyst with an average return of 20.5% and a 56.9% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Praxis Precision Medicines, and Perspective Therapeutics. ;'>

Currently, the analyst consensus on Revolution Medicines is a Strong Buy with an average price target of $182.78, which is a 13.8% upside from current levels. In a report issued on June 16, TipRanks – PerPlexity also upgraded the stock to Buy with a $177.00 price target.

Read More on TEVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).